Strzelczyk A, et al. - A multicenter, retrospective cohort study was conducted to assess effectiveness, retention, and tolerability of brivaracetam (BRV) in genetic generalized epilepsies (GGE) in clinical practice. Study participants were all patients that started BRV in 2016 and 2017. An aggregate of 61 participants were treated with BRV. Researchers reported that use of BRV in GGE was well tolerated, and the 50% responder rates seen in this study were comparable to those seen in regulatory trials for focal epilepsies. They found that an immediate switch from levetiracetam (LEV) to BRV at a ratio of 15:1 was possible. It was noted that the incidence of psychobehavioral adverse events seemed less prominent than under LEV. A switch to BRV could be considered in subjects with LEV-induced adverse events.